Pharmacogenetics: Current Status and Future PerspectivesGUCHELAAR, Henk-Jan.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, issn 1381-6128, 119 p.Serial Issue

Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosineSCHIMMEL, Kirsten; GUCHELAAR, Henk-Jan; VAN KAN, Erik et al.Drug development and industrial pharmacy. 2006, Vol 32, Num 4, pp 497-503, issn 0363-9045, 7 p.Article

Pharmacogenetics of Oral Anticoagulant TherapySCHALEKAMP, T; DE BOER, A.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 187-203, issn 1381-6128, 17 p.Article

Liposomal drug formulations in cancer therapy: 15 years along the roadSLINGERLAND, Marije; GUCHELAAR, Henk-Jan; GELDERBLOM, Hans et al.Drug discovery today. 2012, Vol 17, Num 3-4, pp 160-166, issn 1359-6446, 7 p.Article

Pharmacogenetics of EGFR and VEGF inhibitionPANDER, Jan; GELDERBLOM, Hans; GUCHELAAR, Henk-Jan et al.Drug discovery today. 2007, Vol 12, Num 23-24, pp 1054-1060, issn 1359-6446, 7 p.Article

Pharmacogenetics of Thiopurines in Inflammatory Bowel DiseaseDERIJKS, L. J. J; WONG, D. R.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 145-154, issn 1381-6128, 10 p.Article

Pharmacogenetics in Oncology: A Promising FieldHOUTSMA, D; GUCHELAAR, H. J; GELDERBLOM, H et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 155-163, issn 1381-6128, 9 p.Article

A Computerized Adverse Drug Event Alerting System Using Clinical Rules: A Retrospective and Prospective Comparison with Conventional Medication Surveillance in the NetherlandsROMMERS, Mirjam K; TEEPE-TWISS, Irene M; GUCHELAAR, Henk-Jan et al.Drug safety. 2011, Vol 34, Num 3, pp 233-242, issn 0114-5916, 10 p.Article

Pharmacogenetics in Psychiatry - A Useful Clinical Tool or Wishful Thinking for the Future?KIRCHHEINER, J; SEERINGER, A; VIVIANI, R et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 136-144, issn 1381-6128, 9 p.Article

Pharmacogenetics of Phase I and Phase II Drug MetabolismCRETTOL, Severine; PETROVIC, Nenad; MURRAY, Michael et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 204-219, issn 1381-6128, 16 p.Article

An in vitro study on the Active conversion of Flucytosine to fluorouracil by microorganisms in the human intestinal microfloraVERMES, Andras; KUIJPER, Ed J; GUCHELAAR, Henk-Jan et al.Chemotherapy (Basel). 2003, Vol 49, Num 1-2, pp 17-23, issn 0009-3157, 7 p.Article

Therapeutic modulation of k-ras signaling in colorectal cancerKRENS, Lisanne L; BAAS, Jara M; GELDERBLOM, Hans et al.Drug discovery today. 2010, Vol 15, Num 13-14, pp 502-516, issn 1359-6446, 15 p.Article

Individualizing Calcineurin Inhibitor Therapy in Renal Transplantation - Current Limitations and PerspectivesPRESS, R. R; DE FIJTER, J. W; GUCHELAAR, H.-J et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 176-186, issn 1381-6128, 11 p.Article

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's diseaseKOOLOOS, Wouter M; DE JONG, Dirk J; HUIZINGA, Tom W. J et al.Drug discovery today. 2007, Vol 12, Num 3-4, pp 125-131, issn 1359-6446, 7 p.Article

Genetic Techniques for Pharmacogenetic AnalysesVAN DER STRAATEN, Tahar; VAN SCHAIK, Ron H. N.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 231-237, issn 1381-6128, 7 p.Article

Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1β geneSWEN, Jesse J; BAAK-PABLO, Renee F; GUCHELAAR, Henk-Jan et al.Clinical chemistry and laboratory medicine. 2012, Vol 50, Num 2, pp 279-284, issn 1434-6621, 6 p.Article

Ethical and Social Issues in Pharmacogenomics TestingVIJVERBERG, S. J. H; PIETERS, T; CORNEL, M. C et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 245-252, issn 1381-6128, 8 p.Article

Breath Tests to Phenotype Drug Disposition in OncologyOPDAM, Frans L; MODAK, Anil S; GELDERBLOM, Hans et al.Clinical pharmacokinetics. 2013, Vol 52, Num 11, pp 919-926, issn 0312-5963, 8 p.Article

Pharmacogenetics of Drug TransportersFRANKE, R. M; GARDNER, E. R; SPARREBOOM, A et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 220-230, issn 1381-6128, 11 p.Article

Direct access of drugs to the human brain after intranasal drug administration?MERKUS, Paul; GUCHELAAR, Henk-Jan; BOSCH, D. Andries et al.Neurology. 2003, Vol 60, Num 10, pp 1669-1671, issn 0028-3878, 3 p.Article

Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratioDOUDE VAN TROOSTWIJK, Lous J. A. E; KOOPMANS, Richard P; GUCHELAAR, Henk-Jan et al.Fundamental & clinical pharmacology. 2003, Vol 17, Num 3, pp 355-362, issn 0767-3981, 8 p.Article

Pharmacogenetics in Treatment of Rheumatoid ArthritisKOOLOOS, W. M; HUIZINGA, T. W. J; GUCHELAAR, H.-J et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 164-175, issn 1381-6128, 12 p.Article

Pharmacogenetics and the Pharmaceutical IndustryRAAIJMAKERS, Jan A. M; KOSTER, Ellen S; MAITLAND-VAN DER ZEE, Anke-Hilse et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 2, pp 238-244, issn 1381-6128, 7 p.Article

Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patientsARBOUW, Maurits E. L; MOVIG, Kris L. L; NEEF, Cees et al.European journal of clinical pharmacology. 2007, Vol 63, Num 2, pp 181-187, issn 0031-6970, 7 p.Article

Population pharmacokinetics of flucytosine : Comparison and validation of three models using STS, NPEM, and NONMEMVERMES, Andras; MATHOT, Ron A. A; VAN DER SIJS, I. Heleen et al.Therapeutic drug monitoring. 2000, Vol 22, Num 6, pp 676-687, issn 0163-4356Article